For these studies, we evaluated treatment effects of chronic PAK1 inhibition on 5xFAD mice, both in aged mice (8–9 months at treatment initiation) during the late stages of amyloid plaque deposition, and in young mice (aged 2–3 months at treatment initiation) during the early stages of amyloid plaque deposition. The gene discussed is PAK1; the disease is amyloidosis.